Archive — US — techcrunch
How automotive exec Crystal Brown founded CircNova, an AI drug discovery biotech
CircNova, a Michigan biotech startup founded by Crystal Brown, has secured $3.3 million to develop AI-driven therapies using circular RNA, aiming to address untreated conditions like ovarian cancer and neurodegenerative diseases. Crystal's unconventional transition from the automotive industry to biotech highlights her resilience and adaptability.
Key points
- CircNova raised $3.3 million in seed funding.
- The startup focuses on AI drug discovery using circular RNA.
- Circular RNA is important for regulating biological processes and can target complex health issues.
- Crystal Brown, co-founder and CEO, transitioned from automotive to biotech after assisting a startup.
- CircNova’s AI engine, NovaEngine, predicts circular RNA structures and validates them in a laboratory.
- Brown previously experienced startup failure but has built a strong reputation and secured funding for CircNova.
Why it matters
- The trend of using AI in drug discovery is growing, impacting industries as companies seek faster therapeutic development.
- Crystal Brown's journey reflects the increasing shift of professionals across sectors, particularly from traditional industries to biotech.
- Research and development in circular RNA as a therapeutic area are emerging trends in biotechnology.
CircNova represents a significant advancement in using AI for drug discovery, particularly through circular RNA, addressing unmet medical needs while illustrating the power of resilience in entrepreneurship.